Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Piechaczyk

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
Biochimica Et Biophysica Acta. Reviews on Cancer|April 30, 2019
The AP-1 transcriptional complex: Local switch or remote command?Fabienne Bejjani, Emilie Evanno, Kazem Zibara, et al.
Critical Reviews in Oncology/Hematology|March 23, 2005
Mechanisms of delivery of ubiquitylated proteins to the proteasome: new target for anti-cancer therapy?Rosa Farràs, Guillaume Bossis, Elisabetta Andermarcher, et al.
Molecular and Cellular Biology|October 1, 2003
c-Fos proto-oncoprotein is degraded by the proteasome independently of its own ubiquitinylation in vivoGuillaume Bossis, Patrizia Ferrara, Claire Acquaviva, et al.
The Journal of Investigative Dermatology|February 14, 2002
Skin as a potential organ for ectopic monoclonal antibody productionDanièle Noël, Jean-Eudes Dazard, Mireia Pelegrin, et al.
Biochimie|September 11, 2007
Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: is there a unique answer?Jihane Basbous, Isabelle Jariel-Encontre, Tiphanie Gomard, et al.
Medecine Sciences : M/S|February 5, 2005
[Proteasomal degradation: from addressing of substrates to therapeutical perspectives]Elisabetta Andermarcher, Guillaume Bossis, Rosa Farras, et al.
Molecular and Cellular Biology|March 21, 2007
Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizerJihane Basbous, Dany Chalbos, Robert Hipskind, et al.
Genetic Vaccines and Therapy|March 25, 2004
Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporationNorma Perez, Pascal Bigey, Daniel Scherman, et al.
Human Gene Therapy|September 7, 2002
High in vivo production of a model monoclonal antibody on adenoviral gene transferDanièle Noël, Mireia Pelegrin, Susanne Kramer, et al.
Biochemical Pharmacology|September 6, 2002
Evasion from proteasomal degradation by mutated Fos proteins expressed from FBJ-MSV and FBR-MSV osteosarcomatogenic retrovirusesClaire Acquaviva, Guillaume Bossis, Patrizia Ferrara, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
Biochimica Et Biophysica Acta. Reviews on Cancer|April 30, 2019
The AP-1 transcriptional complex: Local switch or remote command?Fabienne Bejjani, Emilie Evanno, Kazem Zibara, et al.
Critical Reviews in Oncology/Hematology|March 23, 2005
Mechanisms of delivery of ubiquitylated proteins to the proteasome: new target for anti-cancer therapy?Rosa Farràs, Guillaume Bossis, Elisabetta Andermarcher, et al.
Molecular and Cellular Biology|October 1, 2003
c-Fos proto-oncoprotein is degraded by the proteasome independently of its own ubiquitinylation in vivoGuillaume Bossis, Patrizia Ferrara, Claire Acquaviva, et al.
The Journal of Investigative Dermatology|February 14, 2002
Skin as a potential organ for ectopic monoclonal antibody productionDanièle Noël, Jean-Eudes Dazard, Mireia Pelegrin, et al.
Biochimie|September 11, 2007
Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: is there a unique answer?Jihane Basbous, Isabelle Jariel-Encontre, Tiphanie Gomard, et al.
Medecine Sciences : M/S|February 5, 2005
[Proteasomal degradation: from addressing of substrates to therapeutical perspectives]Elisabetta Andermarcher, Guillaume Bossis, Rosa Farras, et al.
Molecular and Cellular Biology|March 21, 2007
Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizerJihane Basbous, Dany Chalbos, Robert Hipskind, et al.
Genetic Vaccines and Therapy|March 25, 2004
Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporationNorma Perez, Pascal Bigey, Daniel Scherman, et al.
Human Gene Therapy|September 7, 2002
High in vivo production of a model monoclonal antibody on adenoviral gene transferDanièle Noël, Mireia Pelegrin, Susanne Kramer, et al.
Biochemical Pharmacology|September 6, 2002
Evasion from proteasomal degradation by mutated Fos proteins expressed from FBJ-MSV and FBR-MSV osteosarcomatogenic retrovirusesClaire Acquaviva, Guillaume Bossis, Patrizia Ferrara, et al.
Pageof 7